25 results about "Bioactive compound" patented technology

The present invention provides a novel room-temperature extraction system and method for cannabis and hemp, utilizing custom membrane filtration to efficiently isolate cannabinoids, terpenes, and other bioactive compounds while reducing energy consumption. This multi-stage system begins with a custom milling machine that preprocesses biomass by separating non-target components, such as cellulose-rich stalks, to improve extraction efficiency. The core extraction process employs a series of custom membranes designed to selectively filter cannabinoids and terpenes, minimizing impurities without the need for traditional sub-zero cooling. Each membrane stage incorporates solvent recovery to recycle ethanol, reducing waste and operational costs. In the final stage, a custom concentrator removes residual ethanol, decarboxylates THCa to THC, and crystallizes sugars to prevent downstream clogging. This room-temperature extraction system significantly enhances yield, purity, and sustainability, making it a scalable and cost-effective solution for cannabis and hemp processing industries, as well as applicable for pharmaceutical and nutraceutical uses.

The present invention relates to a system for the release of bioactive compounds comprising biodegradable colloidal particles with an average size less than 500 nm, where the biodegradable colloidal particles comprise an anionic polysaccharide and a cationic polysaccharide. Furthermore, its method of extraction includes: (a) estimating the stoichiometric charge ratio between an anionic polysaccharide, and a cationic polysaccharide; (b) preparing a solution with the anionic polysaccharide based on the stoichiometric charge ratio and adjusting to an acidic pH; (c) preparing a solution with the cationic polysaccharide based on the stoichiometric charge ratio and adjusting to an acidic pH; (d) adding the solution with the cationic polysaccharide to the solution with the anionic polysaccharide to obtain biodegradable colloidal particles; (e) reducing the particle size of the biodegradable colloidal particles; (f) separating the biodegradable colloidal particles from the supernatant; and (g) resuspending the biodegradable colloidal particles and storing them.

A composition is disclosed. The composition comprises one or more RNAs at least 95% identical to a bioactive milk-derived RNA selected from the group consisting of SEQ ID NOs 1-18. The disclosure also describes a process to generate stable milk RNA-rich extracts comprising SEQ ID 1-18 using natural milk (e.g., Bovine, human, or others), wherein the extract further comprises biologically active compounds. (e.g., nucleic acids molecules, oligosaccharides, proteins, and lipids). In some embodiments, the composition comprises one or more RNAs at least 100% identical to an RNA selected from the group consisting of SEQ ID NOs 1-18. In some embodiments, the composition comprises one or more RNAs at least 95%, 96%, 97%, 98%, or 99% identical to an RNA selected from the group consisting of SEQ ID NOs 1-18. In some embodiments, the composition comprises multiple RNAs.

This disclosure relates to synthetic methods of making bioactive in vivo precursors to plasmalogen compounds and salts thereof and to making plasmalogens and their derivatives and salts thereof. This disclosure also relates to chemical precursors to bioactive compounds and salts thereof. This disclosure further relates to compositions comprising one or more compounds of this disclosure and the use of such compositions in preparing compounds useful in methods of treating diseases and conditions that are beneficially treated by administering plasmalogens or their derivatives or precursors that are transformed in vivo to plasmalogens.

A biphasic nutraceutical system designed to deliver GRAS-certified bioactive compound families across two circadian-aligned phases: a daytime formulation supporting metabolic activation and cognitive readiness, and a nighttime formulation facilitating nutritional regeneration and immune balance. Active compounds are encapsulated respectively within phospholipid-stabilized micellar vesicles for sublingual delivery and pH-sensitive polysaccharide hydrogel matrices for delayed absorption. This dual-phase structure enables non-invasive, phase-specific release and enhances nutrient bioavailability without invoking pharmacological mechanisms. The system integrates principles of nutritional chronobiology and adaptive timing to synchronize absorption with physiological receptivity windows. Exclusively composed of GRAS-aligned functional ingredients, it supports general biological function under non-clinical conditions, remaining fully within the regulatory scope of dietary supplements under 21 CFR §170.30.

A composition and method are provided for producing sustainable ground meat and restructured steak products incorporating an animal fatty tissue substitute. The method includes homogenizing meat trimmings or ground meat without added water to release cellular components, combining the homogenized meat with one or more film-forming agents, fats or fat blends, flavor and color enhancers, and optional binders or bioactive compounds under controlled temperature, pH, and shearing conditions to form an animal fatty tissue substitute, and mixing the substitute with red meat, sustainable red-meat alternatives, or combinations thereof. The resulting compositions exhibit desirable fatty-tissue functionality and allow the production of ground meat products, patties, and restructured steaks, including cuts adhered using transglutaminase. The composition enables partial or substantial replacement of red meat with sustainable alternatives while maintaining flavor, texture, cook performance, and sensory attributes comparable to traditional meat products.

This invention provides an ophthalmic composition for treating and / or preventing visual impairment caused by changes in the structure of the eye's lens, specifically involving alterations in the proteins that form the lens. The ophthalmic composition comprises a combination of a therapeutically effective amount of a polyphenolic compound and a terpene compound, or their salts or crystalline forms, requiring low doses of the bioactive compound to treat the disease with reduced frequency of administration. In particular, the ophthalmic composition of this invention can be used to treat and reverse visual impairments caused by changes in lens structure, such as cataracts, by reversing the lens opacity caused by the disease.

Provided is a compound of the formula (X), or a pharmaceutically acceptable salt, tautomer, stereoisomer, enantiomer, diastereomer thereof, or a mixture thereof, and a conjugate containing the compound. S-D (X)

This invention relates to a process for manufacturing date syrup designed to increase its dietary fiber and bioactive compound content. The process relies on a combination of optimized heat treatments and advanced technologies, such as sonication and high-pressure extraction. This is made possible by rigorous temperature control, which limits caramelization while promoting the extraction of bioactive compounds. The resulting syrups are distinguished by their richness in natural sugars, dietary fiber and polyphenols, while also exhibiting strong antioxidant activity, which gives them remarkable nutritional properties.

The present invention describes the synthesis and use of nanoparticles derived from the leaves of Globularia alypum, a medicinal plant native to the Gafsa region, known for its therapeutic properties. This invention makes it possible to utilize the active compounds of this plant in nanoparticle form in order to improve their efficacy and bioavailability for the treatment of gastrointestinal disorders, particularly constipation. The aqueous extract of Glohularia alypum leaves contains bioactive compounds that act on the digestive system, thus facilitating intestinal transit and reducing constipation. Simultaneously, the use of AgNG allows for better absorption of the active compounds by the body. The preparation process for AgNGs involves mixing the aqueous extract of Glohularia alypum with an Ag NO3 solution and incubating for 15 minutes at 60°C.

This invention provides a method for screening, separating, and identifying trypsin inhibitors, belonging to the field of biomedical technology. The invention first uses colorimetric sensor technology to rapidly identify samples with trypsin-inhibiting activity. Then, using affinity adsorption technology combined with liquid chromatography-mass spectrometry (LC-MS), specific components in the samples with trypsin-inhibiting activity can be identified. Specifically, trypsin is immobilized on Tp-Pa to form a TRY@Tp-Pa affinity chromatography carrier material. The extract to be screened is incubated with the affinity chromatography carrier material, and after removing the unadsorbed liquid, methanol is used to elute the eluent, which contains the bioactive compounds retained on TRY@Tp-Pa. These compounds are the potential active ingredients, and LC-MS is then used to identify the components. The method provided by this invention can efficiently and accurately detect trypsin activity and screen inhibitors, with high screening efficiency and a low false positive rate.

The present invention relates to a polyherbal tablet formulation for the treatment of gouty arthritis and hyperuricemia. The formulation comprises ethanol extracts of six medicinal plants, each contributing specific bioactive compounds with xanthine oxidase (XO) inhibitory, antioxidant, and anti-inflammatory properties. The tablet includes Colchicum autumnale (50mg), Berberis vulgaris (100 mg), Apium graveolens (25 mg), Capparis decidua (25 mg), Fagonia cretica (25 mg), and Trachyspermum ammi (75 mg), combined with a liquid glucose solution to form a 300 mg tablet. The manufacturing method involves ethanol extraction of each plant (70% ethanol, 72 hours), filtration, solvent evaporation under reduced pressure, blending of equal amounts of the extracts with glucose, and drying at 50°C for 12 hours. The resulting formulation demonstrates enhanced therapeutic efficacy in reducing uric acid levels and alleviating joint inflammation, supported by in vitro and in vivo pharmacological assays.

The utility model relates to a formulation for producing Malabar spinach (Basella alba) oil for topical application. The formulation comprises 150–200 mL of coldpressed spinach extract obtained from Malabar spinach leaves, 800 mL of almond oil, 10 mL of lavender oil, and 5 mL of vitamin E. The components are combined to form a homogeneous oil formulation intended for skin application. The formulation utilizes Malabar spinach as a plant-based source of bioactive compounds, blended with almond oil as a base, vitamin E as an antioxidant component, and lavender oil as a fragrance component. The resulting formulation is packaged in suitable containers for storage and use.

The application discloses a TGase-plant protein peptide nanogel delivery system loaded with a fat-soluble active substance, and belongs to the technical field of nanogels. The TGase-plant protein peptide nanogel delivery system loaded with a fat-soluble active substance is prepared by reasonably utilizing plant protein peptides. In order to solve the problems of poor stability of soybean peptides and possible unsatisfactory embedding effect, TGase is added to the nanogel delivery system, so that the effective embedding of the fat-soluble active substance can be met, and the effective release of the fat-soluble active substance can also be met. Once the nanogel is ingested, the nanogel will be degraded in the gastrointestinal tract, so that the stable release of the active substance is ensured. Meanwhile, the peptides or amino acids generated after digestion also have biological activity, and can play a synergistic role with the bioactive compounds.

A process for preparing a composition comprising biomass from Aspergillus and bioactive compounds, the process including culturing Aspergillus in a liquid medium comprising an assimilable carbon source and inorganic nutrients. The culturing process includes (i) a fermentation under aerobic conditions followed by (ii) a fermentation under stress conditions comprising hypoxic stress and pH stress conditions. Compositions obtainable by this process and food or feed supplements containing the compositions are also provided.

The invention described herein relates to selectively-bred, matrix-blank organisms selected to: a) not express a bioactive compound or group of compounds; yet b) express, at least substantially qualitatively, most other non-bioactive compounds present in an analytically active comparator organism, wherein the organisms are used to generate a matrix-blank reference material with a chemical profile that resembles that of the comparator organism less the active compound or group of compounds, as well as methods of making the organisms and uses thereof. The invention described herein further relates to the matrix-blank reference materials, methods of making, and uses thereof.The invention described herein relates to selectively-bred, matrix-blank organisms selected to: a) not express a bioactive compound or group of compounds; yet b) express, at least substantially qualitatively, most other non-bioactive compounds present in an analytically active comparator organism, wherein the organisms are used to generate a matrix-blank reference material with a chemical profile that resembles that of the comparator organism less the active compound or group of compounds, as well as methods of making the organisms and uses thereof. The invention described herein further relates to the matrix-blank reference materials, methods of making, and uses thereof.

A method of extracting bioactive compounds suitable for human and animal consumption from ethanol brewer's stillage. Stillage comprising spent grains suspended in water is provided from an ethanol plant. A lyophilized enzyme is added to the stillage. Ethanol is added to the stillage to form a mixture of ethanol and stillage. The mixture of ethanol and stillage is mixed and ethanol is extracted from the mixture to form a solution of bioactive compounds dissolved in extracted ethanol and spent grains containing the lyophilized enzyme. The bioactive compounds from the extracted ethanol are then separated by distillation or evaporation of the ethanol.

The present invention relates to a bioactive scaffold comprising a silver-loaded antimicrobial composition, which acts as a therapeutic device, especially a scaffold, for wound healing and other applications related to the field of tissue engineering. The antimicrobial composition of the invention mainly comprises at least one absorbable matrix for cell-matrix and cell-cell interactions (a natural polymer), a calcium cross-linking component for forming a fibrin gel in situ, and a nanoemulsion containing colloidal silver nanoparticles as a bioactive compound to help control biofilm and infections in the wound. The structures comprising the antimicrobial composition act as dressings and means for aiding the healing of chronic wounds by assisting in infection management and / or improving the biological activity in chronic wounds.

A method for automated therapy discovery includes: accessing a corpus of scientific publications; compiling a population of semantic concepts from the corpus of scientific publications into a vector space model; deriving domains of concepts in the vector space model based on proximity to domain descriptors in the vector space model; deriving association scores and action characteristics between connected concepts, based on proximity and action descriptors in the vector space model; generating a semantic network; receiving a query for a target concept and a target domain at a research portal; isolating a set of edges between a target node and a subset of nodes; identifying subsets of concepts along the set of edges; generating hypotheses for directions and magnitudes of effects of subsets of concepts on the target concept based on association scores and action characteristics stored in connections along the set of edges; and returning hypotheses to the research portal.

This invention discloses a biomembrane for screening and evaluating V2R inhibitors, its preparation method, and its application. The preparation method includes: amylating and carboxylating a glass fiber membrane to obtain a carboxylated glass fiber membrane; and reacting the carboxylated glass fiber membrane with O... 6 -Benzylguanine reacts to produce O 6 -Benzylguanine-modified glass fiber membrane; and, making the O 6 A novel biomembrane for screening and evaluating V2R inhibitors was prepared by incubating a benzylguanine-modified glass fiber membrane with a cell membrane. This invention provides a novel biomembrane for screening and evaluating V2R inhibitors, and this biomembrane can be used for targeted screening and evaluation of potentially V2R-antagonistic bioactive compounds in natural products.